K-757 and K-833

DRUG2 trials

Sponsors

Kallyope Inc.

Conditions

ObesityType 2 Diabetes Mellitus in Obese

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

CompletedNCT05890950

Kallyope Inc.Obesity, Type 2 Diabetes Mellitus in Obese

Start: 2023-03-13End: 2023-07-12Updated: 2023-10-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

CompletedNCT05900531

Kallyope Inc.Obesity

Start: 2022-09-21End: 2023-05-31Updated: 2024-11-22